These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 38976217)
1. Long-Term Follow-Up before and during Riluzole Treatment in Six Patients from Two Families with Spinocerebellar Ataxia Type 7. Agnese S; Chiara C; Radouil T; Iveta C; Francesco P; Gianmarco B; Marco S; Theresa Z; Giovanni R; Silvia R Cerebellum; 2024 Jul; ():. PubMed ID: 38976217 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial. Coarelli G; Heinzmann A; Ewenczyk C; Fischer C; Chupin M; Monin ML; Hurmic H; Calvas F; Calvas P; Goizet C; Thobois S; Anheim M; Nguyen K; Devos D; Verny C; Ricigliano VAG; Mangin JF; Brice A; Tezenas du Montcel S; Durr A Lancet Neurol; 2022 Mar; 21(3):225-233. PubMed ID: 35063116 [TBL] [Abstract][Full Text] [Related]
3. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Romano S; Coarelli G; Marcotulli C; Leonardi L; Piccolo F; Spadaro M; Frontali M; Ferraldeschi M; Vulpiani MC; Ponzelli F; Salvetti M; Orzi F; Petrucci A; Vanacore N; Casali C; Ristori G Lancet Neurol; 2015 Oct; 14(10):985-91. PubMed ID: 26321318 [TBL] [Abstract][Full Text] [Related]
4. Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Jacobi H; du Montcel ST; Bauer P; Giunti P; Cook A; Labrum R; Parkinson MH; Durr A; Brice A; Charles P; Marelli C; Mariotti C; Nanetti L; Panzeri M; Rakowicz M; Sulek A; Sobanska A; Schmitz-Hübsch T; Schöls L; Hengel H; Baliko L; Melegh B; Filla A; Antenora A; Infante J; Berciano J; van de Warrenburg BP; Timmann D; Szymanski S; Boesch S; Kang JS; Pandolfo M; Schulz JB; Molho S; Diallo A; Klockgether T Lancet Neurol; 2015 Nov; 14(11):1101-8. PubMed ID: 26377379 [TBL] [Abstract][Full Text] [Related]
5. Clinical and genetic analysis of spinocerebellar ataxia type 7 (SCA7) in Zambian families. Atadzhanov M; Smith DC; Mwaba MH; Siddiqi OK; Bryer A; Greenberg LJ Cerebellum Ataxias; 2017; 4():17. PubMed ID: 29214039 [TBL] [Abstract][Full Text] [Related]
6. Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes. Vogel AP; Folker J; Poole ML Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD008953. PubMed ID: 25348587 [TBL] [Abstract][Full Text] [Related]
7. Use of Riluzole for the Treatment of Hereditary Ataxias: A Systematic Review. Ayala IN; Aziz S; Argudo JM; Yepez M; Camacho M; Ojeda D; Aguirre AS; Oña S; Andrade AF; Vasudhar A; Moncayo JA; Hassen G; Ortiz JF; Tambo W Brain Sci; 2022 Aug; 12(8):. PubMed ID: 36009103 [TBL] [Abstract][Full Text] [Related]
8. Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia Type 3: a Randomized, Double-Blind, Sham-Controlled Trial. Maas RPPWM; Teerenstra S; Toni I; Klockgether T; Schutter DJLG; van de Warrenburg BPC Neurotherapeutics; 2022 Jul; 19(4):1259-1272. PubMed ID: 35501469 [TBL] [Abstract][Full Text] [Related]
9. A longitudinal investigation into cognition and disease progression in spinocerebellar ataxia types 1, 2, 3, 6, and 7. Moriarty A; Cook A; Hunt H; Adams ME; Cipolotti L; Giunti P Orphanet J Rare Dis; 2016 Jun; 11(1):82. PubMed ID: 27333979 [TBL] [Abstract][Full Text] [Related]
10. Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study. Jacobi H; du Montcel ST; Romanzetti S; Harmuth F; Mariotti C; Nanetti L; Rakowicz M; Makowicz G; Durr A; Monin ML; Filla A; Roca A; Schöls L; Hengel H; Infante J; Kang JS; Timmann D; Casali C; Masciullo M; Baliko L; Melegh B; Nachbauer W; Bürk-Gergs K; Schulz JB; Riess O; Reetz K; Klockgether T Lancet Neurol; 2020 Sep; 19(9):738-747. PubMed ID: 32822634 [TBL] [Abstract][Full Text] [Related]
11. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3. Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650 [TBL] [Abstract][Full Text] [Related]
12. A Proposal for Classification of Retinal Degeneration in Spinocerebellar Ataxia Type 7. Marianelli BF; Filho FMR; Salles MV; de Andrade JBC; Pedroso JL; Sallum JMF; Barsottini OGP Cerebellum; 2021 Jun; 20(3):384-391. PubMed ID: 33196954 [TBL] [Abstract][Full Text] [Related]
13. ATXN7-Related Cone-Rod Dystrophy: The Integrated Functional Evaluation of the Cerebellum (CERMOI) Study. Nassisi M; Coarelli G; Blanchard B; Dubec-Fleury C; Drine K; Kitic N; Sancho S; Hilab R; Tezenas du Montcel S; Junge C; Lane R; Arnold HM; Durr A; Audo I JAMA Ophthalmol; 2024 Apr; 142(4):301-308. PubMed ID: 38421662 [TBL] [Abstract][Full Text] [Related]
14. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Ristori G; Romano S; Visconti A; Cannoni S; Spadaro M; Frontali M; Pontieri FE; Vanacore N; Salvetti M Neurology; 2010 Mar; 74(10):839-45. PubMed ID: 20211908 [TBL] [Abstract][Full Text] [Related]
15. Cerebellar transcranial direct current stimulation in spinocerebellar ataxia type 3 (SCA3-tDCS): rationale and protocol of a randomized, double-blind, sham-controlled study. Maas RPPWM; Toni I; Doorduin J; Klockgether T; Schutter DJLG; van de Warrenburg BPC BMC Neurol; 2019 Jul; 19(1):149. PubMed ID: 31272408 [TBL] [Abstract][Full Text] [Related]
16. Patterns of motor signs in spinocerebellar ataxia type 3 at the start of follow-up in a reference unit. Pulido-Valdeolivas I; Gómez-Andrés D; Sanz-Gallego I; Rausell E; Arpa J Cerebellum Ataxias; 2016; 3():4. PubMed ID: 26909158 [TBL] [Abstract][Full Text] [Related]
17. [Spinocerebellar ataxia type 8 in Russian patients]. Nuzhnyi EP; Abramycheva NY; Chkhartishvili IA; Protopopova AO; Fedotova EY; Illarioshkin SN Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(8):106-111. PubMed ID: 36036411 [TBL] [Abstract][Full Text] [Related]